Our product pipeline covers several advanced mAb biosimilar candidates with near-term commercial visibility. 漢利康® (rituximab injection), our first product, has been granted NDA approval by the NMPA as the first biosimilar in China in February, 2019.
Leveraging the experience of biosimilar development, we are developing comprehensive bio-innovative pipeline and driving worldwide clinical studies of novel products for the long-term growth.
We have versatile in-house combination therapy portfolio with a focus on anti-PD-1/PD-L1 mAbs to capture future immuno-oncology opportunities with the aim of providing affordable and effective therapies.
Fully leveraging the global research and development platform, we have developed a diversified and advanced pipeline, covering more than 20 biosimilars, and bio-innovative candidates, with significant potential for a variety of PD-1/PD-L1-based immuno-oncology combination therapies.
The manufacturing facility, established since 2016, alongwith the supporting quality management system, have been granted GMP Certification from EU and China.
We have assembled a professional commercial team with rich industry experience. With the successful launch of 漢利康® (rituximab injection), we will improve the future business planning with comprehensive product marketing strategy.
In Henlius, employees are our most important resources and most valuable assets. Talents are top on our priorities.
We value talents by retaining them, developing them and putting right people to right place.